• Group sales revenue down 11% QoQ and 12% pcp, with mixed trading across core channels
• Domestic retail resilient, International revenue impacted by timing factors
• Practitioner channel trading softer, with stabilization towards quarter end
• Focused on disciplined execution, working capital management and pathway to profitability

Nuchev Limited has reported its Q3 FY26 results, with group sales revenue of $4.7 million, down 11% quarter-on-quarter and 12% year-on-year. Trading performance was mixed across the company's core channels. The Oli6® Nutritionals domestic retail business remained resilient, supported by ongoing demand across grocery and pharmacy channels and solid customer execution in the market. However, International activity was uneven during the quarter, with shipment timing, regulatory timing in key export markets, launch timing and customer ordering patterns continuing to affect revenue conversion. The Practitioner channel also remained softer through the quarter, although trading stabilized toward the end. The company continued to actively manage working capital, with cash at 31 March 2026 of $2.1 million. During the quarter, the Board considered management's strategic review of the business and priorities for the next phase of growth, reinforcing the opportunity to leverage Nuchev's existing platform across retail, practitioner, distribution and innovation. The company remains focused on disciplined execution, working capital management and improving the pathway to profitability over time.

The company is focused on disciplined execution across its core channels, progression of its broader innovation and portfolio expansion pipeline, and careful management of working capital as it positions the business for its next phase of growth.